Nicotinamide Riboside Supplementation Boosts NAD+ and Lowers Inflammatory Immune Signaling in Lupus: Clinical Findings

Objectives

To explore the anti-inflammatory effects of NR in monocytes (a type of white blood cell; immune cell) extracted from young, healthy subjects following supplementation. Additionally, the findings were tested in ex vivo in monocytes extracted from patients with systemic lupus erythematosus (SLE).

Journal

Journal of Clinical Investigation

Key Outcomes

Ex Vivo:

• NR reduced cytokine expression and type-I interferon (IFN) signaling (which plays an important role in the human immune response) in monocytes from healthy subjects and SLE patients.

In Vivo:

• NR supplementation increased whole blood NAD+ levels, as well as levels of related NAD+ metabolites.
• NR supplementation also replicated the effects observed with ex-vivo NR administration, resulting in a similar reduction in type-I IFN signaling in the young, healthy subjects.

Duration

1 week

Dose

1000 mg

Study Design

Ex Vivo:
Monocytes were extracted from young, healthy subjects and patients with systemic lupus erythematosus (SLE) and then treated with NR

In Vivo:
Randomized, double-blind, placebo-controlled, pilot study in 35 young, healthy subjects